Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy.
CPS
IC
TPS
programmed death-ligand 1
survival
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
27 Aug 2020
27 Aug 2020
Historique:
received:
02
07
2020
revised:
16
08
2020
accepted:
24
08
2020
entrez:
2
9
2020
pubmed:
2
9
2020
medline:
2
9
2020
Statut:
epublish
Résumé
Reports on the prognostic role of programmed death-ligand 1 (PD-L1) expression in rectal cancer are controversial. We investigated expression patterns and changes of PD-L1 in rectal cancer patients undergoing neoadjuvant chemoradiotherapy (CRT). Seventy-two patients diagnosed with rectal cancer and/or treated with fluorouracil-based neoadjuvant CRT at the Department of Internal Medicine III of the Paracelsus Medical University Salzburg (Austria) between January 2003 and October 2012 were included. PD-L1 scoring was performed according to the tumor proportion score (TPS), combined positive score (CPS), and immune cell score (IC). PD-L1 TPS prior to neoadjuvant CRT had a statistically significant impact on survival (median: ≤1%: 95.4 months (95% CI: 51.8-not reached) vs. >1%: not reached,
Identifiants
pubmed: 32867256
pii: jcm9092775
doi: 10.3390/jcm9092775
pmc: PMC7563312
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Paracelsus Medical University Salzburg
ID : RISE R15/05/075-HUE
Organisme : Oesterreichische Krebshilfe
ID : not available
Références
Appl Immunohistochem Mol Morphol. 2016 Jul;24(6):392-7
pubmed: 27333219
Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2965-70
pubmed: 25392179
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Sci Transl Med. 2017 Apr 12;9(385):
pubmed: 28404866
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
J Clin Oncol. 2016 Sep 20;34(27):3300-7
pubmed: 27480145
Lancet Oncol. 2012 Jul;13(7):679-87
pubmed: 22627104
Eur J Cancer. 2013 Jun;49(9):2233-42
pubmed: 23478000
Clin Cancer Res. 2020 Oct 1;26(19):5198-5207
pubmed: 32669377
Eur J Cancer. 2018 Mar;91:11-20
pubmed: 29328976
J Clin Oncol. 2011 Jul 10;29(20):2773-80
pubmed: 21606427
Int J Colorectal Dis. 1997;12(1):19-23
pubmed: 9112145
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Appl Immunohistochem Mol Morphol. 2019 Feb;27(2):92-100
pubmed: 29346180
Cancer Immunol Immunother. 2019 Feb;68(2):283-296
pubmed: 30448924
Lancet Oncol. 2017 Nov;18(11):1483-1492
pubmed: 28967485
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Lancet Oncol. 2015 Aug;16(8):979-89
pubmed: 26189067
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
J Clin Oncol. 2018 Mar 10;36(8):773-779
pubmed: 29355075
J Cancer Res Clin Oncol. 2019 Apr;145(4):1043-1053
pubmed: 30874889
J Clin Oncol. 2019 Nov 20;37(33):3111-3123
pubmed: 31593484
Eur J Cancer. 2016 Sep;65:52-60
pubmed: 27468145
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Front Pharmacol. 2019 Feb 28;10:139
pubmed: 30873025
Lancet. 2017 Jan 7;389(10064):67-76
pubmed: 27939400
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv263
pubmed: 29741565
Arch Pathol Lab Med. 2019 Mar;143(3):330-337
pubmed: 30028179
J Dig Dis. 2017 Oct;18(10):574-581
pubmed: 28851046
Int J Clin Oncol. 2016 Oct;21(5):946-952
pubmed: 26919982
Lancet Oncol. 2019 Jun;20(6):849-861
pubmed: 31003911